BioCryst Pharmaceuticals BCRX License and other revenues — Total trade receivables

Similar metrics at other companies

CHDNTrade receivables — Accounts receivable

$58M+18.1%

ABUSRevenue from collaborations and licenses — License receivable from Genevant

$178.7M—

CSVCemetery — Trade and financed receivables

$33.66M+28.0%

NGSRentals — Trade accounts receivable

$19.87M+58.6%

NGSSales and aftermarket services — Trade accounts receivable

$2.55M+46.9%

CSVFuneral Home — Trade and financed receivables

$5.77M-17.3%

FAQ

What is BioCryst Pharmaceuticals's license and other revenues — total trade receivables?

BioCryst Pharmaceuticals (BCRX) reported license and other revenues — total trade receivables of $6.18M in Q2 2026.

What does license and other revenues — total trade receivables mean?

This metric measures the total outstanding amounts owed to the company by customers or partners for services rendered or licenses granted within the specific segment. It represents the value of credit extended to counterparties that has not yet been collected in cash. High levels of trade receivables relative to revenue may indicate potential collection risks or changes in payment terms with strategic partners.